G1 Therapeutics' COSELA Recommended In Updated Small Cell Lung Cancer Guidelines From American Society Of Clinical Oncology
Portfolio Pulse from Benzinga Newsdesk
The American Society of Clinical Oncology has updated its guidelines for small cell lung cancer to include G1 Therapeutics' COSELA. This recommendation could potentially increase the usage of COSELA, benefiting G1 Therapeutics.
October 18, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
G1 Therapeutics' COSELA has been included in the updated guidelines for small cell lung cancer by the American Society of Clinical Oncology. This could potentially increase the usage of COSELA, positively impacting G1 Therapeutics.
The inclusion of COSELA in the updated guidelines by the American Society of Clinical Oncology could lead to increased usage of the drug. This could potentially increase revenues for G1 Therapeutics, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100